Analysis on Usage of Oral Chinese Patent Medicine in the Inpatient Department of Shiyan Taihe Hospital from 2020 to 2022
Objective:To analyze the current situation of Chinese patent medicine in the inpatient department of Shiyan Taihe Hospital from 2020 and 2022 and explore the rationality of its use,so as to provide a basis for clinical rational,safe,effective and economic use of Chinese patent medicine.Methods:According to the usage of oral Chinese patent medicine in the inpatient department of Shiyan Taihe Hospital from 2020 and 2022,the name,variety,dosage,sales amount,total drug amount and the number of discharged people were counted.The frequency of drug use(DDDs),the average daily cost(DDC)and the proportion of Chinese patent medicine in the total amount of drugs,and the average cost of Chinese patent medicine per case were calculated and analyzed.Results:According to the ranking of dosage forms,injection,capsule and tablet have ranked among the top three in sales in the past three years.Blood stasis removing drug,anti-tumor drug and dampness removing drug ranked the top three in terms of drug efficacy category in terms of sales amount for three consecutive years.Ranked by DDDs,Diyu Shengbai Tablets(地榆升白片),Danning Tablets(胆宁片),Shengxuening Tablets(生血宁片)and Maizhiling Tablets(迈之灵片)have ranked high for three consecutive years,and the DDDs of Diyu Shengbai Tablet,Danning Tablet and Maizhiling Tablet have shown a significant upward trend over the past three years.Ranked by DDC,there has been a decreasing trend over the past three years,with Kang'ai Injection(康艾注射液),Brucea Javanica Oil Soft Capsule(鸦胆子油软胶囊),and Shuganning Injection(舒肝宁注射液)ranking high for three consecutive years.The proportion of Chinese patent medicine in the total amount of drugs in the inpatient department of the hospital declined year by year from 2020 to 2022,and the average drug cost per case declined year by year.Conclusion:With the strengthening of hospital control over Chinese patent medicine,the sales amount of Chinese patent medicine and the average drug cost per case declined year by year,and the usage is more standardized.The usage of some higher DDC Chinese patent medicine gradually reduced,and the economic pressure of patients further reduced.
万方数据
